[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"electric-stimulation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:electric-stimulation-therapy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100651244","motor-cortex-stimulation-for-post-stroke-thalamic-pain-100651244",false,"NCT07758829","Motor Cortex Stimulation for Post-Stroke Thalamic Pain","A Study on Mechanisms and Predictive Factors of Motor Cortex Stimulation for Post-Stroke Thalamic Pain Based on Multimodal Imaging","Inclusion Criteria:\n\n* Age between 18 and 80 years. Diagnosed with chronic post-stroke central pain with a pain duration of at least 1 year, with stroke localized to the thalamus.\n\nVisual Analog Scale (VAS) pain score ≥ 5 at baseline. Poor response to or intolerance of conventional pharmacotherapy for pain. Medically suitable for surgical treatment (no coagulopathy, no infection at surgical site, no severe psychiatric disorders, etc.).\n\nVoluntarily agrees to receive motor cortex stimulation (MCS) treatment. Able to communicate effectively with researchers and willing to comply with all study requirements.\n\nSufficient cognitive ability to use the patient programmer and patient programmer charger.\n\nExclusion Criteria:\n\n* History of alcohol, drug, or substance abuse or dependence within the past 12 months.\n\nTrigeminal neuralgia or atypical facial pain. Advanced cardiovascular or other systemic disease that precludes surgical intervention.\n\nPrior history of ablative or related intracranial surgery. Presence of other neurological disorders, such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, or brain\u002Fspinal cord tumors.\n\nImplanted drug pump and\u002For another implantable device (e.g., cardiac pacemaker, defibrillator, cochlear implant, other neurostimulation systems such as spinal cord stimulator or deep brain stimulator).\n\nMetastatic malignancy or untreated localized malignancy. Pregnancy, breastfeeding, planned pregnancy, or women of childbearing potential without reliable contraceptive measures.\n\nSevere depression or anxiety (as determined by clinical assessment). Any other condition deemed unsuitable for participation by the investigator.","ALL","18 Years","80 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to investigate the mechanisms and predictive factors of motor cortex stimulation (MCS) for treating post-stroke thalamic pain, a challenging central neuropathic pain condition. Approximately 25% of patients show no short-term response to MCS, and about 20% experience long-term efficacy decay, yet the underlying analgesic mechanisms remain unclear and objective predictive biomarkers are lacking.\n\nThis study aims to answer the following main questions:\n\nHow does MCS modulate thalamic pain through the coordinated interaction of structural connectivity, functional network dynamics, and metabolic balance in the brain? What are the distinct neuroimaging characteristics that differentiate short-term non-responders, long-term responders, and those with long-term efficacy decay? Which multimodal imaging biomarkers can reliably predict short-term and long-term MCS efficacy? Participants will undergo a two-stage MCS surgical procedure. In stage I, epidural electrodes are implanted over the motor cortex, followed by a 2-week external trial stimulation. Participants who achieve a ≥50% reduction in Visual Analog Scale (VAS) pain score will proceed to stage II, receiving an implanted pulse generator for long-term stimulation. Those who do not respond in the short term will have the electrodes removed without undergoing stage II implantation.\n\nAll participants will complete baseline clinical assessments and multimodal MRI scans (including T1, DTI, resting-state fMRI, and MRS) before surgery. Participants who receive the permanent implant will undergo follow-up clinical evaluations and repeat MRI scans at 3 and 6 months post-surgery.\n\nResearchers will compare imaging features across three outcome groups-short-term non-responders, long-term responders, and long-term decay group-to identify predictive biomarkers. Multimodal imaging data will be integrated using LASSO regression to build prediction models for both short-term screening and long-term efficacy warning.\n\nThis research is expected to establish a \"mechanism exploration - efficacy prediction - clinical decision\" paradigm, providing objective imaging-based evidence to guide patient selection and postoperative management for MCS treatment.",[27,28,29,30],"Central Post-stroke Pain","Stroke","Electric Stimulation Therapy","Multimodal Imaging",[32,33,34,35,36,37],"Post-Stroke Thalamic Pain","Motor Cortex Stimulation","Neuromodulation","Multimodal Magnetic Resonance Imaging","Predictive Biomarkers","Brain Networks","NOT_YET_RECRUITING","2026-08-06",{"date":41,"type":42},"2026-08-11","ACTUAL",{"date":44,"type":21},"2026-09-01",{"date":46,"type":21},"2029-06-30",{"name":48,"class":49},"Aerospace Center Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100556048","evaluating-safety-and-feasibility-of-transcutaneous-spinal-cord-stimulation-following-traumatic-and-non-traumatic-spinal-cord-injury-a-pilot-study-100556048","NCT06520020","Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study","STIM","Inclusion Criteria:\n\n* Age: = 18 years and = 80 years.\n* Written informed consent by patient and\u002For legal authorized representative (LAR).\n* No other life-threatening condition.\n* No evidence of sepsis.\n* No evidence of superficial skin infection at site of surgery and intervention.\n* An established diagnosis of either:\n\n  * cervical myelopathy with modified Japanese Orthopaedic Association score of 8-14, or\n  * acute cervical \u002F thoracic SCI with ASIA Impairment Scale grade A-D (as assessed within 72 hours of injury) with neurologic level of injury (NLI) from C2 to T12.\n* The ability to undergo, or have had, surgical intervention. -. The ability to undergo transcutaneous intervention including study procedures in the posterior cervical or thoracic midline at or after 14 days from surgery.\n\nExclusion Criteria:\n\n* Any concomitant impairment of the upper and lower limb at baseline that could potentially confound the neurologic assessments; including but not limited to traumatic or disease conditions like brachial plexus injury, peripheral neuropathy, spinal hematoma, transverse myelitis, non-compressive myelopathy, dementia, and Parkinson's disease.\n* mJOA of \\>= 15 and \\\u003C= 7, or AIS grade E tSCI at baseline assessment.\n* Currently involved in another non-observational ntSCI or tSCI study, or receiving another interventional drug, that could interfere with recordings and confound adverse events.\n* Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation, at discretion of the treating surgeon and\u002For principal investigator.\n* Unable to commit to the follow-up schedule.\n* Recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study.\n* Any condition likely to result in the patient's death within the next 12 months.\n* Prisoner.\n* Pregnancy.\n* Cardiac pacemaker dependent, unable to undergo electrical stimulation.\n* Brain implant, skull prosthesis, plate and screws limiting transcranial stimulation.\n* Tattoo at site of skin electrode that causes heat\u002Fpain during stimulation.\n* Subjects who in the opinion of the investigator are not suitable for inclusion in the study, with reason documented.",{"count":58,"type":21},30,[24],"The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 total patients, 10 patients in each of 3 groups:\n\n1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention.\n2. Early tSCI screened during the hospital admission when cervical\u002Fthoracic spinal injury was diagnosed.\n3. Delayed tSCI (control) screened 6-24 months after acute cervical\u002Fthoracic spinal injury.",[62,29,63,64],"Spinal Cord Stimulation","Traumatic Spinal Cord Injury","Cervical Myelopathy",[66,67,68,69,70],"Stimulation","Transcutaneous","MagStim","Transcranial","Magnetic","RECRUITING","2026-07-02",{"date":74,"type":42},"2026-07-07",{"date":76,"type":42},"2024-10-23",{"date":78,"type":21},"2027-12-01",{"name":80,"class":49},"Francis Farhadi",1]